Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 3/2006

01-03-2006 | Letter to the Editor

Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease

Authors: Angela Casquero, Alicia Barroso, Manuel L. Fernández Guerrero, Miguel Górgolas

Published in: Annals of Hematology | Issue 3/2006

Login to get access

Abstract

Several approved therapies for multicentric Castleman disease (MCD) cannot be uniformly applied due to intolerable side effects. There is also a high percentage of recurrence of this disease despite treatment. Rituximab may be effective in controlling MCD in a subset of patients. This paper includes a brief case report and an extensive review of previously published cases. We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.
Literature
1.
Oksenhendler E, Duarte M, Soulier J et al (1996) Multicentric CD in HIV infection: a clinical and pathological study of 20 patients. AIDS 10:61PubMedCrossRef
2.
Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP (2002) Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 35:880–882PubMedCrossRef
3.
Du MQ, Liu H, Diss TC et al (2001) Kaposi sarcoma-associated herpesvirus infects monotypic (IgMlambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130PubMedCrossRef
4.
Marcelin AG, Aaron L, Mateus C et al (2003) Rituximab therapy for HIV-associated Castleman disease. Blood 102:2786PubMedCrossRef
5.
Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH (2003) A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti CD-20 monoclonal antibody. Ann Hematol 82:766–768PubMedCrossRef
6.
Kofteridis DP, Tzagarakis N, Mixaki I, Maganas E, Xilouri E, Stathopoulos EN, Eliopoilos GD, Gikas A (2004) Multicentric Castleman’s disease: prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patients. AIDS 18(3):585–586PubMedCrossRef
7.
Marrache F, Larroche C, Memain N, Bouchoud O, Robineau M, Hermone O, Lortholary O (2003) Prolonged remission of HIV-associated multicentric Castleman’s disease with anti-CD20 monoclonal antibody as primary therapy. AIDS 17:1409–1410PubMedCrossRef
8.
Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, Manganaro D, Fasan M, Moroni M, Galli M, Parravicini C (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473–3475PubMedCrossRef
9.
Newsom-Davis T, Bower M, Wildfire A, Thirlwell C, Nelson M, Gazzard B, Stebbing J (2004) Resolution of AIDS-related Castleman’s disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma 45(9):1939–1941PubMedCrossRef
10.
Ide M, Ogawa E, Kasagi K, Kawachi Y, Ogino T (2003) Successful treatment of multicentric Castleman’s disease with bilateral orbital tumour using rituximab. Br J Haematol 121:818PubMedCrossRef
Metadata
Title
Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease
Authors
Angela Casquero
Alicia Barroso
Manuel L. Fernández Guerrero
Miguel Górgolas
Publication date
01-03-2006
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 3/2006
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-005-0038-4

Other articles of this Issue 3/2006

Annals of Hematology 3/2006 Go to the issue

Review Article

Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias

Letter to the Editor

Acute eosinophilic pneumonia after allogeneic hematopoietic stem cell transplantation

Letter to the Editor

Unusual relapse of acute myeloid leukemia: granulocytic sarcoma presenting as an acute paraplegia

Letter to the Editor

Cutaneous zygomycosis at catheter insertion site in AML-M4Eo

Letter to the Editor

Is splenectomy a contraindication for patients with myelodysplastic syndromes complicated by splenomegaly?

Letter to the Editor

Lymphoma presenting as chronic aortic dissection in Marfan syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits